Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 2/20 | 0.61 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.61 |
| ▸ | CES2 | O00748 | 2/20 | 0.52 |
| ▸ | CES1 | P23141 | 2/20 | 0.52 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.44 |
| ▸ | CHRNG | P07510 | 1/20 | 0.44 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CHRND | Q07001 | 1/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 1/20 | 0.42 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2417941 | 0.84 | GABRA1 (0.54) | GABRA1GABRB1GLRA1GAAHTT | |
| SCHEMBL2416215 | 0.83 | GABRA1 (0.70) | GABRA1GABRB1GLRA1GAAHTT | |
| SCHEMBL28078271 | 0.82 | GABRA1 (0.78) | GABRA1GABRB1SLC6A2GLRA1GAA | |
| SCHEMBL8077465 | 0.81 | GABRA1 (0.57) | GABRA1GABRB1CES2CES1GLRA1 | |
| SCHEMBL2417465 | 0.80 | GABRA1 (0.70) | GABRA1GABRB1GAAHTTBCL2 | |
| SCHEMBL8081975 | 0.80 | GABRA1 (0.64) | GABRA1GABRB1CES2CES1SLC6A3 | |
| SCHEMBL8077296 | 0.79 | GABRA1 (0.69) | GABRA1GABRB1CES2CES1CHRNB2 | |
| SCHEMBL28111646 | 0.79 | CES2 (0.47) | GABRA1GABRB1CES2CES1CHRNA1 | |
| SCHEMBL8077321 | 0.79 | GABRA1 (0.63) | GABRA1GABRB1CES2CES1SLC6A2 | |
| SCHEMBL8080530 | 0.79 | GABRA1 (0.54) | GABRA1GABRB1GLRA1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2520290-B1 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE LLC (US) | 2014-12-10 | — | — | EP | disclosed |
| EP-2520290-A1 | Propofol analogs, process for their preparation, and methods of use | Abraxis BioScience, LLC (US) | 2012-11-07 | — | — | EP | disclosed |
| US-7586008-B2 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-7586008-B2 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2009-09-08 | — | — | US | disclosed |
| US-20080275100-A1 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080275100-A1 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20070185217-A1 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| US-20070185217-A1 | Propofol analogs, process for their preparation, and methods of use | ABRAXIS BIOSCIENCE, INC. (US) | 2007-08-09 | — | — | US | disclosed |
| WO-2005063665-A1 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | ABRAXIS BIOSCIENCE, INC (US) | 2005-07-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275100-A1 | PROPOFOL ANALOGS, PROCESS FOR THEIR PREPARATION, AND METHODS OF USE | CYP3A5, CYP3A4, GABARAP | GABRA1 32/4885GABRB1 81/4885CES2 479/4885 |
| US-20070185217-A1 | Propofol analogs, process for their preparation, and methods of use | CYP3A5, CYP3A4, GABARAP | GABRA1 32/4885GABRB1 81/4885CES2 479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.